LEGENDS

InvestHack #09Recap

Who Would Pay $100M for Breakthrough IP

Amit Grover on finding buyers before funding research and testing technology before acquiring the rights.

Friday, 6 November 20265:00 PM Dubai1:00 PM London8:00 AM New York

Amit Grover, Founder & Managing Partner of Grover & Company

What happened in the session

  1. 01

    Why Grover liquidated his Alternative Protein fund in less than two years and what he learned about the cost of reaching customers

  2. 02

    How demand-based investing shapes his assessment of universities, research teams and potential buyers

  3. 03

    How a one- to two-year licence lets a company test technology before buying the rights at a valuation agreed in advance

If there’s no demand, then you’re wasting money, resources and time.
Amit Grover
Amit Grover beside an excerpt from his interview: If there’s no demand, then you’re wasting money.

Amit Grover

Founder & Managing Partner, Grover & Company

Amit Grover is the founder and managing partner of Grover & Company and CEO of Grover Impact Ventures. He has more than 27 years of experience in marketing, management consulting and venture capital, including senior roles at ITC Ltd, Lavazza Coffee and Pernod Ricard. He holds an MBA from Victoria University of Wellington in New Zealand.

After liquidating his Alternative Protein fund, Grover set up an investment arm and partnered with universities in crop genetics. At Legends InvestHack #9, he describes his approach to demand-based investing: assess the university and research team, identify companies that could use the result, and establish what those buyers would need to see before paying for the intellectual property.

If there’s no demand, then you’re wasting money, resources and time.

Evaluates

Looks at the university’s strengths and what the scientists have published on similar work.

Checks demand

Maps potential buyers and what they would need the technology to demonstrate before paying for the rights.

Finds partners

Looks for established companies that already have manufacturing, distribution and customer acquisition in place.

Structures deals

Describes a one- to two-year licensing trial, with a valuation agreed in advance if the buyer later chooses to acquire the rights.

2008Grover & Company founded
Crop geneticsResearch investment focus
1–2 yearsLicensing trial in his example